Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma (Q36752747)

16 August 2017

1 reference

title

Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma (English)

1 reference

16 August 2017

0 references

Christoph W M Reuter

1

1 reference

16 August 2017

Michael A Morgan

2

1 reference

16 August 2017

Viktor Grünwald

3

1 reference

16 August 2017

Thomas R W Herrmann

4

1 reference

16 August 2017

Martin Burchardt

5

1 reference

16 August 2017

Arnold Ganser

6

1 reference

16 August 2017

6 March 2007

1 reference

16 August 2017

World Journal of Urology

1 reference

16 August 2017

25

1 reference

16 August 2017

1

1 reference

16 August 2017

59-72

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-007-0152-0

16 August 2017

0 references

cites work

The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-007-0152-0

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-007-0152-0

Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-007-0152-0

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

12 December 2020

1 reference

12 December 2020

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

1 reference

12 December 2020

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

12 December 2020

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation

1 reference

12 December 2020

Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]

1 reference

12 December 2020

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

12 December 2020

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

1 reference

12 December 2020

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

1 reference

12 December 2020

PI3K/Akt/mTOR pathway as a target for cancer therapy

1 reference

12 December 2020

The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing

1 reference

12 December 2020

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

12 December 2020

Novel approaches in the therapy of metastatic renal cell carcinoma.

1 reference

12 December 2020

VEGF receptor signalling - in control of vascular function

1 reference

12 December 2020

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model

1 reference

12 December 2020

BAY 43-9006: preclinical data

1 reference

12 December 2020

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer.

1 reference

12 December 2020

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium

1 reference

12 December 2020

The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy

1 reference

12 December 2020

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

12 December 2020

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

1 reference

12 December 2020

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

12 December 2020

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1007/S00345-007-0152-0

1 reference

16 August 2017

1 reference